RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals, Inc.

Biotechnology • Healthcare • Salt Lake City, UT, United States • RXRX (NMS)

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
simplywall.st • Jan 6
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Yahoo Finance
Yahoo Finance • Dec 21
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - The Motley Fool
The Motley Fool • Jan 1
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
AOL.com • Jan 5
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Quiver Quantitative • Jan 2

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has RECURSION PHARMACEUTICALS, INC. had layoffs?
No layoff events have been recorded for RECURSION PHARMACEUTICALS, INC. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does RECURSION PHARMACEUTICALS, INC. have?
RECURSION PHARMACEUTICALS, INC. has approximately 800 employees.
What industry is RECURSION PHARMACEUTICALS, INC. in?
RECURSION PHARMACEUTICALS, INC. operates in the Biotechnology industry, within the Healthcare sector.
Is RECURSION PHARMACEUTICALS, INC. a publicly traded company?
Yes, RECURSION PHARMACEUTICALS, INC. is publicly traded under the ticker symbol RXRX on the NMS. The company has a market capitalization of approximately $2.23 billion.
Where is RECURSION PHARMACEUTICALS, INC. headquartered?
RECURSION PHARMACEUTICALS, INC. is headquartered in Salt Lake City, UT, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.